Melanoma, NRAS-mutated

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search
Section editor
Bethbuchbinder.jpg
Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
Boston, MA

LinkedIn

Note: these are biomarker-specific regimens, please see the main melanoma page for other regimens.

1 regimens on this page
1 variants on this page


Advanced or metastatic disease, TKI-naive

Binimetinib monotherapy

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Ascierto et al. 2013 Phase II
Dummer et al. 2017 (NEMO) Phase III (E) Dacarbazine Superior PFS

Chemotherapy

Continued indefinitely

References

  1. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. Epub 2013 Feb 13. link to original article contains protocol PubMed
  2. NEMO: Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. Epub 2017 Mar 8. link to original article contains protocol PubMed